Core Viewpoint - Changshan Pharmaceutical (300255) is expected to report a net profit loss of between 190 million to 285 million yuan for 2025, marking a year-on-year decline of 14.24% to 23.84%, continuing its trend of losses for the third consecutive year [1] Financial Performance - For the first three quarters of 2025, the company reported an operating income of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit loss of 44.82 million yuan, indicating a significant increase in losses in the fourth quarter [3] - The company experienced a net profit loss of 1.24 billion yuan in 2023, followed by a loss of 249 million yuan in 2024, and is projected to incur another loss of around 200 million yuan in 2025 [3] - Revenue has been declining since 2022, with a year-on-year decrease of 21.3% in 2022, 39.6% in 2023, and 26.9% in 2024 [3] Industry Competition - The heparin industry is facing intensified competition, leading to a decline in revenue and low gross margins for the company's core heparin products [3] - The company is adjusting its sales strategy due to the nature of centralized procurement, which has resulted in a significant reduction in sales expenses [3] Product Development - The company is betting on its innovative drug, Aibennate, a GLP-1 single-target agonist, which has received acceptance for its market approval application for type 2 diabetes [4] - There is uncertainty regarding the approval timeline for Aibennate, as well as for its clinical trial application for weight loss indications [4] Regulatory Issues - The company's distributor was involved in a bribery case, which has raised concerns about its market practices [5][6] - The Shanghai market supervision authority found that the distributor engaged in commercial bribery, leading to a fine of 300,000 yuan [6]

格隆汇1月30日丨常山药业(300255.SZ)发布2025年度业绩预告，报告期内，归属于上市公司股东的净利 润为亏损1.90亿元～2.85亿元，上年同期亏损2.49亿元；扣除非经常性损益后的净利润为亏损1.91亿元～ 2.86亿元，上年同期亏损2.86亿元。2025年，肝素药品行业竞争加剧，公司核心产品肝素制剂系列产品 收入下降，同时受集采及原材料价格波动等因素综合影响，毛利率维持较低水平，这是公司亏损的主要 原因。 ...

Core Viewpoint - Changshan Pharmaceutical (300255) forecasts a net profit attributable to shareholders of between -190 million to -285 million yuan for 2025, representing a year-on-year decline of 14.24% to 23.84% [1] Group 1: Financial Performance - The expected net profit for 2025 is projected to be between -190 million to -285 million yuan, indicating a significant decline compared to the previous year [1] - The decline in profit is attributed to intensified competition in the heparin drug industry and a decrease in revenue from core heparin product series [1] Group 2: Market and Operational Factors - The company cites the impact of centralized procurement policies and fluctuations in raw material prices as contributing factors to maintaining a low gross margin [1] - In response to the centralized procurement policy for its main products, the company is adjusting its sales strategy, optimizing sales team configurations, and reducing distributor levels and terminal maintenance costs [1] - Sales expenses for 2025 are expected to decrease significantly compared to the previous year due to refined management of market expenses [1]

Core Viewpoint - The company expects a negative net profit for the fiscal year 2025, with a projected range for net profit attributable to shareholders between -285 million yuan and -190 million yuan, compared to -249 million yuan in the same period last year [1] Financial Performance - The expected net profit range for 2025 is between -286 million yuan and -191 million yuan, with the previous year's figure being -286 million yuan [1] - The company reported a net profit of -249 million yuan in the same period last year [1] Industry Context - The heparin drug industry is experiencing intensified competition, leading to a decline in revenue from the company's core heparin preparation products [1] - Factors such as centralized procurement and fluctuations in raw material prices are contributing to a low gross margin, which is a primary reason for the company's anticipated losses [1]